FDA Grants Accelerated Approval to GSK's Neladalkib for Lung Cancer
The U.S. Food and Drug Administration has granted accelerated approval to neladalkib, a kinase inhibitor designed for lung cancer treatment. This therapeutic asset is now part of GSK's oncology portfolio following the company's $10.6 billion acquisition of Nuvalent earlier this year. The approval marks a significant milestone in validating GSK's recent strategic investment in Boston-based biopharma firm Nuvalent. By integrating neladalkib into its pipeline, GSK strengthens its position in the competitive oncology market and expands its specialized lung cancer treatment options.

Tickers: $GSK
Topics: accelerated approval biopharma acquisition lung cancer therapy